BRPI0620125A8 - método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra - Google Patents
método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostraInfo
- Publication number
- BRPI0620125A8 BRPI0620125A8 BRPI0620125A BRPI0620125A BRPI0620125A8 BR PI0620125 A8 BRPI0620125 A8 BR PI0620125A8 BR PI0620125 A BRPI0620125 A BR PI0620125A BR PI0620125 A BRPI0620125 A BR PI0620125A BR PI0620125 A8 BRPI0620125 A8 BR PI0620125A8
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- isolating
- sample
- recombinant vector
- biological function
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 5
- 230000008827 biological function Effects 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000004845 protein aggregation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
método para regulação de redução dafunção biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma proteína de uma amostra a presente invenção pertence ao campo da proteômica funcional e mais particularmente ao campo da agregação de proteínas. a invenção divulga um método para interferênciana função de uma proteína alvo e utiliza uma moléculaconstruída não-naturalmente por um usuário, designada como interferente, que possui uma especificidade para uma proteína alvo e que induz agregação ao contatar a referida proteína alvo. a presente invenção também divulga as referidas moléculas interferentes e sua utilização em aplicações terapêuticas.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75324505P | 2005-12-22 | 2005-12-22 | |
| US60/753.245 | 2005-12-22 | ||
| EP0511261.1 | 2005-12-22 | ||
| EP05112761.1 | 2005-12-22 | ||
| EP05112761 | 2005-12-22 | ||
| US87207906P | 2006-12-01 | 2006-12-01 | |
| US60/872.079 | 2006-12-01 | ||
| EP06125189.8 | 2006-12-01 | ||
| EP06125189 | 2006-12-01 | ||
| PCT/EP2006/070184 WO2007071789A1 (en) | 2005-12-22 | 2006-12-22 | Means and methods for mediating protein interference |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0620125A2 BRPI0620125A2 (pt) | 2011-11-01 |
| BRPI0620125A8 true BRPI0620125A8 (pt) | 2019-01-15 |
| BRPI0620125B1 BRPI0620125B1 (pt) | 2022-05-17 |
Family
ID=37762689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0620125-3A BRPI0620125B1 (pt) | 2005-12-22 | 2006-12-22 | Método para regulação de redução da função biológica de uma proteína, e método para isolar uma proteína de uma amostra |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9095556B2 (pt) |
| EP (2) | EP2345417A1 (pt) |
| AU (1) | AU2006326940B2 (pt) |
| BR (1) | BRPI0620125B1 (pt) |
| CA (1) | CA2632331C (pt) |
| HR (1) | HRP20121016T1 (pt) |
| IL (1) | IL192001A (pt) |
| PL (1) | PL1962883T3 (pt) |
| WO (1) | WO2007071789A1 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345417A1 (en) | 2005-12-22 | 2011-07-20 | Vib Vzw | Means and methods for mediating protein interference |
| US8669418B2 (en) | 2005-12-22 | 2014-03-11 | Vib Vzw | Means and methods for mediating protein interference |
| CN101772512A (zh) * | 2007-06-04 | 2010-07-07 | 弗拉芒区生物技术研究所 | 用交叉β结构靶向诱导蛋白质聚集 |
| WO2010129890A2 (en) * | 2009-05-08 | 2010-11-11 | Virginia Tech Intellectual Properties, Inc. | Compounds and methods for inhibiting platelet aggregation |
| US20130149297A1 (en) | 2010-07-02 | 2013-06-13 | Vib Vzw | Role of fragile x mental retardation gene and protein in cancer metastasis |
| CA2805263A1 (en) * | 2010-07-29 | 2012-02-02 | Dow Agrosciences Llc | Strains of agrobacterium modified to increase plant transformation frequency |
| GB201012845D0 (en) | 2010-07-30 | 2010-09-15 | Vib Vzw | Inhibition of dicer function for treatment of cancer |
| ES2679995T3 (es) * | 2011-03-11 | 2018-09-03 | Vib Vzw | Moléculas y métodos para la inhibición y detección de proteínas |
| WO2012130785A1 (en) | 2011-03-25 | 2012-10-04 | Vib Vzw | Methods for screening inhibitors of tumour associated protein aggregation |
| GB201106845D0 (en) | 2011-04-26 | 2011-06-01 | Vib Vzw | Methods and means to produce abiotic stress tolerant plants |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| WO2012175735A1 (en) | 2011-06-23 | 2012-12-27 | Vib Vzw | A20 inhibitors for the treatment of respiratory viral infections |
| WO2013121042A1 (en) | 2012-02-16 | 2013-08-22 | Vib Vzw | PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER |
| KR101460439B1 (ko) | 2012-05-14 | 2014-11-12 | 서울대학교산학협력단 | 나노프로브 및 이를 이용한 표적 물질 검출방법 |
| US9660745B2 (en) * | 2012-12-12 | 2017-05-23 | At&T Intellectual Property I, L.P. | Geocast-based file transfer |
| WO2014118123A1 (en) | 2013-01-29 | 2014-08-07 | The University Court Of The University Of Glasgow | Methods and means for increasing stress tolerance and biomass in plants |
| EP3017049B1 (en) | 2013-07-01 | 2018-08-22 | Bayer CropScience NV | Methods and means for modulating flowering time in monocot plants |
| US20170159065A1 (en) | 2014-07-08 | 2017-06-08 | Vib Vzw | Means and methods to increase plant yield |
| WO2016050512A1 (en) | 2014-10-03 | 2016-04-07 | Bayer Cropscience Nv | Methods and means for increasing stress tolerance and biomass in plants |
| CA3001932A1 (en) | 2015-10-16 | 2017-04-20 | Bayer Cropscience Nv | Brassica plants with altered properties in seed production |
| EP3621979A1 (en) | 2017-05-09 | 2020-03-18 | VIB vzw | Means and methods for treating bacterial infections |
| WO2019110693A1 (en) | 2017-12-05 | 2019-06-13 | Celyad S.A. | Compositions and methods for improving persistence of cells for adoptive transfer |
| US11639496B2 (en) | 2017-12-05 | 2023-05-02 | Celyad S.A. | Reducing fratricide of immune cells expressing NKG2D-based receptors |
| CN115484971A (zh) * | 2020-02-19 | 2022-12-16 | 艾琳治疗公司 | 靶向蛋白的分子 |
| US20230090247A1 (en) | 2020-02-19 | 2023-03-23 | Aelin Therapeutics | Molecules targeting ras protein |
| WO2022184821A1 (en) | 2021-03-03 | 2022-09-09 | Vib Vzw | Beta-lactamase inhibitors |
| WO2023131616A1 (en) | 2022-01-05 | 2023-07-13 | Vib Vzw | Means and methods to increase abiotic stress tolerance in plants |
| WO2023131637A1 (en) | 2022-01-06 | 2023-07-13 | Vib Vzw | Improved silage grasses |
| WO2023144199A1 (en) | 2022-01-26 | 2023-08-03 | Vib Vzw | Plants having reduced levels of bitter taste metabolites |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4478946A (en) | 1981-07-02 | 1984-10-23 | South African Inventions Development Corporation | Carrier bound immunosorbent |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4550017A (en) | 1982-10-15 | 1985-10-29 | Syntex (U.S.A.) Inc. | Fluorescence screening for blood typing |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US6159748A (en) | 1995-03-13 | 2000-12-12 | Affinitech, Ltd | Evaluation of autoimmune diseases using a multiple parameter latex bead suspension and flow cytometry |
| CA2214247C (en) * | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| US6627616B2 (en) | 1995-12-13 | 2003-09-30 | Mirus Corporation | Intravascular delivery of non-viral nucleic acid |
| DE69834527T2 (de) | 1997-07-01 | 2007-05-10 | VLP Watertown Limited Partnership, Watertown | Verfahren zur Geschlechtsbestimmung von Säuger-Nachkommenschaft |
| US6399317B1 (en) | 1998-04-15 | 2002-06-04 | Utah State University | Real time detection of antigens |
| US6682940B2 (en) | 1999-05-04 | 2004-01-27 | Dan A. Pankowsky | Products and methods for single parameter and multiparameter phenotyping of cells |
| US20030064384A1 (en) * | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
| US20050026165A1 (en) | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| EP1325930A1 (en) | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| KR20050042082A (ko) | 2002-05-31 | 2005-05-04 | 시젠 피티와이 리미티드 | 막 투과 서열로부터 유도된 자가 융합 또는 자가 응집단백질 |
| GB0216972D0 (en) * | 2002-07-22 | 2002-08-28 | Univ Lancaster | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases |
| US20050203010A1 (en) * | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| US7940302B2 (en) * | 2004-09-15 | 2011-05-10 | The Regents Of The University Of California | Apparatus and method for privacy protection of data collection in pervasive environments |
| EP2345417A1 (en) | 2005-12-22 | 2011-07-20 | Vib Vzw | Means and methods for mediating protein interference |
-
2006
- 2006-12-22 EP EP10188217A patent/EP2345417A1/en not_active Withdrawn
- 2006-12-22 BR BRPI0620125-3A patent/BRPI0620125B1/pt not_active IP Right Cessation
- 2006-12-22 EP EP06830822A patent/EP1962883B1/en active Active
- 2006-12-22 HR HRP20121016TT patent/HRP20121016T1/hr unknown
- 2006-12-22 WO PCT/EP2006/070184 patent/WO2007071789A1/en not_active Ceased
- 2006-12-22 CA CA2632331A patent/CA2632331C/en active Active
- 2006-12-22 AU AU2006326940A patent/AU2006326940B2/en not_active Ceased
- 2006-12-22 PL PL06830822T patent/PL1962883T3/pl unknown
-
2008
- 2008-06-05 IL IL192001A patent/IL192001A/en active IP Right Grant
- 2008-06-20 US US12/214,761 patent/US9095556B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL1962883T3 (pl) | 2013-02-28 |
| HRP20121016T1 (hr) | 2013-01-31 |
| BRPI0620125A2 (pt) | 2011-11-01 |
| AU2006326940B2 (en) | 2012-04-19 |
| CA2632331A1 (en) | 2007-06-28 |
| EP1962883B1 (en) | 2012-10-10 |
| WO2007071789A1 (en) | 2007-06-28 |
| US9095556B2 (en) | 2015-08-04 |
| AU2006326940A1 (en) | 2007-06-28 |
| EP1962883A1 (en) | 2008-09-03 |
| IL192001A0 (en) | 2008-12-29 |
| BRPI0620125B1 (pt) | 2022-05-17 |
| US20090012275A1 (en) | 2009-01-08 |
| IL192001A (en) | 2011-10-31 |
| CA2632331C (en) | 2015-02-10 |
| EP2345417A1 (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017204797B2 (en) | Antibodies with modified isoelectric points | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| BR112012004697A2 (pt) | purificação melhorada de proteína através de uma eluição da proteína a modificada. | |
| MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
| MY163480A (en) | Sclerostin binding agents | |
| MX2009005189A (es) | Anticuerpos humanos monoclonales para btla y metodos de uso. | |
| BR112012017124C1 (pt) | Método para produzir e para purificar um multímero polipeptídico | |
| EA201690946A1 (ru) | Мутанты fgf21 и их применение | |
| PE20081392A1 (es) | Moleculas de enlace de lingo | |
| EP4512422A3 (en) | Homogenous antibody populations | |
| WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
| MY174493A (en) | Binding agents | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| EA200870020A1 (ru) | Человеческие моноклональные антитела против о8е | |
| BR112016011025A2 (pt) | polipeptídeos anticorpo e seus usos | |
| UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| CL2008003910A1 (es) | Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida. | |
| EA200801531A1 (ru) | Способы регулирования содержания маннозы в рекомбинантных белках | |
| MX2009005776A (es) | Anticuerpos humanos que se enlazan al cd 22 y sus usos. | |
| EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
| WO2008085987A3 (en) | Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display | |
| WO2015023553A3 (en) | Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules | |
| BRPI0812348B8 (pt) | método para regulação descedente ou de redução da função biológica de uma proteína,molécula quimérica,vetor recombinate e método para isolar uma proteína de uma amostra |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2806 DE 15-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |